# PPP2R2A

Source: https://onco.cc/targets/ppp2r2a/  
OnCo record `ppp2r2a` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PPP2R2A (Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.

## Summary

Substrate-recognition subunit of protein phosphatase 2A (PP2A) that plays a key role in cell cycle by controlling mitosis entry and exit. Involved in chromosome clustering during late mitosis by mediating dephosphorylation of MKI67. Essential for serine/threonine-protein phosphatase 2A-mediated dephosphorylation of WEE1, preventing its ubiquitin-mediated proteolysis, increasing WEE1 protein levels, and promoting the G2/M checkpoint.

CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Olaparib and PARP Inhibitor ABT-888.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: protein phosphatase 2 regulatory subunit Balpha; Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform; PR52A; PR55A; B55A; PR55alpha; B55alpha
- Tags: cancer-genes-wave
- Symbol: PPP2R2A
- Class: other
- Biology: Substrate-recognition subunit of protein phosphatase 2A (PP2A) that plays a key role in cell cycle by controlling mitosis entry and exit. Involved in chromosome clustering during late mitosis by mediating dephosphorylation of MKI67. Essential for serine/threonine-protein phosphatase 2A-mediated dephosphorylation of WEE1, preventing its ubiquitin-mediated proteolysis, increasing WEE1 protein levels, and promoting the G2/M checkpoint. Locus 8p21.2 (HGNC).
- Where found: Prostate cancer: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9304: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9304
- UniProt P63151: https://www.uniprot.org/uniprotkb/P63151/entry
- NCBI Gene 5520: https://www.ncbi.nlm.nih.gov/gene/5520
- Ensembl ENSG00000221914: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000221914

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/ppp2r2a.json